Lenacapavir Injection + Lenacapavir Tablet
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Pre-exposure Prophylaxis
Conditions
HIV Pre-exposure Prophylaxis
Trial Timeline
Jul 22, 2025 → Sep 1, 2028
NCT ID
NCT07047716About Lenacapavir Injection + Lenacapavir Tablet
Lenacapavir Injection + Lenacapavir Tablet is a phase 3 stage product being developed by Gilead Sciences for HIV Pre-exposure Prophylaxis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07047716. Target conditions include HIV Pre-exposure Prophylaxis.
What happened to similar drugs?
0 of 3 similar drugs in HIV Pre-exposure Prophylaxis were approved
Approved (0) Terminated (0) Active (3)
🔄Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDFGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07047716 | Phase 3 | Recruiting |
Competing Products
7 competing products in HIV Pre-exposure Prophylaxis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |
| Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only) | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |
| F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo | Gilead Sciences | Phase 3 | 44 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 39 |
| Monoclonal antibody JST-010 + Placebo | Evotec | Phase 1 | 30 |